ReActiv8
-
Spine
Mainstay Medical to Showcase ReActiv8 and Key Clinical Data at the 13th German Spine Congress of the DWG
December 03, 2018 DUBLIN–(BUSINESS WIRE)–Regulatory News: Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin:…
Read More » -
Financial
Mainstay Medical to seek further funding as full-year losses mount
Aug 24, 2017 – Charlie Taylor Dublin-listed Mainstay Medical, a company that is targeting chronic back pain with an implantable device, is…
Read More » -
Hospitals
Mainstay Medical Achieves CE Marking for ReActiv8® and Prepares for Commercial Launch in Germany
May 25, 2016 – DUBLIN–(BUSINESS WIRE)–Regulatory News: Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange:…
Read More » -
Financial
Mainstay Medical – Interim Management Statement
Dublin, Ireland – 9 November 2015: Mainstay Medical International plc (Mainstay or the Company, Euronext Paris: MSTY.PA and ESM of…
Read More » -
Hospitals
Mainstay Medical Gains Approval to Start US Clinical Trial of ReActiv8®
Dublin – Ireland, 29th May 2015 – Mainstay Medical International plc (“Mainstay” or the “Company” listed on Euronext Paris: MSTY.PA…
Read More »